Business
Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates
Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) Completed Studies to Support Process Optimization through Cell Line Switch for Budoprutug and Filed Additional Patent Applications to Further Strengthen Intellectual Property Position Expanded Pipeline to Include CLYM116, an Anti-APRIL (A PRoliferation-Inducing Ligand) Monoclonal Antibo
About this update from Climb Bio, Inc.
[{"type":"image","alt":"Climb Bio, Inc.","displaySize":"","headline":null,"caption":"Climb Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/96b5fbbb4dd8bc4bbccc298a6909629c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/upR1wQHp9TCZxvAhULaG8g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/96b5fbbb4dd8bc4bbccc298a6909629c","width":300,"height":300}},"lazy":false},{"type":"text","content":"Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE)","length":212,"tagName":"p"},{"type":"text","content":"Completed Studies to Support Process Optimization through Cell Line Switch for Budoprutug and Filed Additional Patent Applications to Further Strengthen Intellectual Property Position","length":183,"tagName":"p"},{"type":"text","content":"Expanded Pipeline to Include CLYM116, an Anti-APRIL (A PRoliferation-Inducing Ligand) Monoclonal Antibody for Treatment of IgA Nephropathy (IgAN)","length":145,"tagName":"p"},{"type":"text","content":"Appointed Perrin Wilson, Ph.D. as Chief Business Officer","length":56,"tagName":"p"},{"type":"text","content":"Ended 2024 in a Strong Financial Position, with Cash Runway Expected Through 2027","length":81,"tagName":"p"},{"type":"text","content":"WELLESLEY HILLS, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the quarter and year ended December 31, 2024, provided a business update, and reiterated anticipated program milestones.","length":355,"tagName":"p"},{"type":"text","content":"“2024 was a transformational year for Climb Bio, as we rebranded the company and embarked on our mission to bring more inspired medicines to patients living with immune-mediated diseases,” said Aoife Brennan, President and CEO of Climb Bio. “Our momentum continues in 2025, which marks a critical year of execution across our portfolio. Our cornerstone asset, budoprutug, a potentially best-in-class anti-CD19 monoclonal antibody, is being developed for three initial indications: p...